Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous intra-arterial mesoangioblast therapy for m.3243A>G mitochondrial myopathy
NL-OMON42959Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Nov 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesoangioblasts in Mitochondrial myopathies (MM) and Mitochondriopathy, sponsored by Erasmus MC. Primary endpoint: Safety. Planned start Nov 2016; status: withdrawn.
02
Drugs
autologous mesoangioblasts
03
Conditions
Mitochondrial myopathies (MM)Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON42959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42959.